The panel discusses key learnings from recent studies in non-clear cell RCC subtypes and the need to better understand disease biology to develop optimized, histology-specific therapies rather than extrapolating clear cell treatment approaches.
FDA Approves Belzutifan in Adult/Pediatric Pheochromocytoma and Paraganglioma
Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.
A Sneak Peek at 2025 ASCO From the GU Perspective
Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.
EVP Before Consolidative Surgery Optimizes Responses in Urothelial Cancer
No 90-day mortality was observed among patients who were treated with EVP followed by surgery for advanced urothelial cancer.
Finding Ways to Break the Mold in GU Oncology
Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.
Chemoradiation Prolongs OS, Maintains QOL in Advanced Gallbladder Cancers
Chemoradiotherapy resulted in lower incidence of local progression, prompting an evaluation of resectability in patients with advanced gallbladder cancers.
A World of Research, Care, and Science: Becoming A Radiation Oncologist
James B. Yu, MD, MHS, FASTRO, didn’t always envision himself as a radiation oncologist, but now works tirelessly to treat patients and advance research for genitourinary cancers.